期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型免疫调节肽佐剂CEL-1000

A newly peptide with adjuvant activity CEL-1000
下载PDF
导出
摘要 CEL-1000是一种新型的免疫调节肽,它在抗疟疾、人类免疫缺陷病毒(H IV)、单纯疱疹病毒(HSV)感染和肿瘤疫苗的研制方面具有潜在的佐剂活性,能促进1型辅助性T淋巴细胞(Th1)型免疫应答。 CEL-1000 （derG） is a newly immunomodulatory peptide. It appears potential adjuvant activity in vaccine studies of anti-malaria, herpes simplex vinus （ HSV ） , human immunodefieieney virus （HIV） and tumor which direct to the immune response toward Thl.
作者 刘艳青 毛旭虎 邹全明
机构地区 第三军医大学医学检验系临床微生物及免疫学教研室暨重庆市生物制药工程技术研究中心
出处 《医学研究生学报》 CAS 2006年第3期261-262,266,共3页 Journal of Medical Postgraduates
基金 国家自然科学基金资助项目(批准号:30100161)
关键词 CEL-1000肽 佐剂 1型辅助性T淋巴细胞型免疫应答 CEL-1000 peptide Adjuvant T-helper 1 immune response
分类号 R967 [医药卫生—药理学]
  • 相关文献

参考文献7

  • 1Charoenvit Y,Goel N,Whelan M,et al.CEL-1000-a peptide with adjuvant activity for TH1 immune responses[J].Vaccine,2004,22(19):2368-2373.
  • 2于哲,范清宇.树突状细胞肿瘤疫苗的研究进展[J].医学研究生学报,2005,18(1):63-66. 被引量：8
  • 3Goel N,Zimmerman D,Rosenthal KS.A L.E.A.P.S.heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits TH1 responses and protections[J].Vaccine,2003,21(27-30):4410-4420.
  • 4Zimmerman D,Rosenthal KS.The L.E.A.P.S.approach to vaccine development[J].Frontiers Bioscience,2005,10(8):790-798.
  • 5Goel N,Zimmerman D,Rosenthal KS.Ligand epitope antigen presentation system vaccines against Herpes simplex virus[J].Frontiers Bioscience,2005,10(6):966-974.
  • 6Zimmerman D,Lloyd JP,Heisey D,et al.Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1SF2 p17) and peptide segments of human β-2-microglobulin or MHC II β chain[J].Vaccine,2001,19(32):4750-4759.
  • 7Charoenvit Y,Brice GT,Bacon D,et al.A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner[J].Antimicrob Agents Chemother,2004,48(7):2455-2463.

二级参考文献32

  • 1Kono K, Takahashi A, Sugai H et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer[J]. Clin Cancer Res, 2002, 8(11):3394-3400.
  • 2Schaefer BC, Schaefer ML, Kappler JW et al. Observation of antigen-dependent CD8+ T-cell/ dendritic cell interactions in vivo[J]. Cell Immunol, 2001, 214(2):110-122.
  • 3Labarriere N, Bretaudeau L, Gervois N et al. Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen[J]. Int J Cancer, 2002, 101(3):280-286.
  • 4Siders WM, Vergilis KL, Johnson C et al. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells[J]. Mol Ther, 2003, 7(4):498-505.
  • 5Schadendorf D, Paschen A, Sun Y et al. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma[J]. Immunol Lett, 2000, 74(1):67-74.
  • 6Gong J, Nikrui N, Chen D et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity[J]. J Immunol, 2000, 165(3):1705-1711.
  • 7Tanaka H, Shimizu K, Hayashi T et al. Therapeutic immune response induced by electrofusion of dendritic and tumor cells[J]. Cell Immunol, 2002, 220(1):1-12.
  • 8Orentas RJ, Schauer D, Bin Q et al. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine[J]. Cell Immunol, 2001,213(1):4-13.
  • 9Cao X, Zhang W, Wang J et al. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells[J]. Immunology, 1999,97(4):616-625.
  • 10Lamparski HG, Metha-Damani A, Yao JY et al. Production and characterization of clinical grade exosomes derived from dendritic cells[J]. J Immunol Methods, 2002, 270(2):211-226.

共引文献7

医学研究生学报
2006年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部